查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954300

疾病治療生物製藥市場分析及預測（至2035年）：依類型、產品、服務、技術、應用、最終使用者、流程、部署及設備分類

Biologics for Disease Treatment Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Deployment, Device
出版日期: | 出版商: Global Insight Services | 英文 365 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，治療性生物製藥市場規模將從2024年的5,610億美元成長至1,4,0​​31億美元，複合年成長率約為11.6%。治療性生物製藥市場涵蓋單株抗體、疫苗和細胞療法等生物來源治療產品。這些生物製藥用於治療包括癌症、自體免疫疾病和感染疾病在內的複雜疾病。生物技術進步、個人化醫療以及監管核准是推動市場成長的主要因素，尤其關注療效和安全性。慢性病發病率的上升和對創新治療方法需求的不斷成長，促使研發投入大幅增加，從而推動了市場成長。

受生物技術和個人化醫療進步的推動，治療性生物製藥市場正經歷強勁成長。單株抗體因其針對標靶化疾病的特異性和療效而被廣泛應用，其中成長速度最快。在這一領域，腫瘤治療應用佔據主導地位，反映出對創新癌症治療方法的迫切需求。緊隨其後的是疫苗領域，其成長速度位居第二，這主要得益於人們對預防醫學和疫苗接種計劃的日益重視。感染疾病的增加和新型疫苗平台的開發也促進了這一成長。細胞療法領域也展現出巨大的潛力，尤其是在再生醫學和慢性病管理方面。生物技術公司與大型製藥公司之間的策略聯盟和合作進一步鞏固了市場，促進了創新並加速了產品開發。監管支援和生產技術的進步正在推動市場動態，確保高品質生物製藥的穩定供應。

市場區隔
類型 單株抗體、重組蛋白、細胞療法、基因療法、疫苗、融合蛋白、抗體藥物複合體、生物相似藥
產品 治療性蛋白質、胜肽類藥物、酵素、荷爾蒙、凝血因子、干擾素、細胞激素
服務 生產製造、研發、法規支援、臨床試驗、品質保證、供應鏈管理、生物製程
科技 重組DNA技術、融合瘤技術、基因改造技術、CRISPR技術、奈米技術、生物列印
目的 腫瘤科、自體免疫疾病、感染疾病、心血管疾病、神經系統疾病、代謝性疾病、罕見疾病
最終用戶 醫院、診所、研究機構、生物製藥公司、受託研究機構、學術機構
流程 上游工程、下​​游加工、配方、填充和包裝
部署 內部生產、外包、混合模式
裝置 生物反應器、離心機、層析法系統、過濾系統

在治療性生物製藥市場，市場佔有率由少數幾家主要企業主導，定價策略也反映了生物製藥的高階特性。在創新和技術進步的推動下，市場正經歷新產品上市的激增。各公司致力於開發針對特定疾病的生物製藥，並提高其療效。定價競爭異常激烈，製造商需要在成本效益和盈利之間尋求平衡。戰略夥伴關係和合作是該市場的一個顯著特徵，它們推動了新型生物製藥的推出。競爭基準分析表明，老牌製藥巨頭保持著強大的市場地位，而新興生物技術公司則透過提供利基產品來擴大市場佔有率。監管具有高度影響力，嚴格的指導方針影響市場動態。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 在核准流程中發揮關鍵作用，影響產品上市的速度和成功率。市場數據顯示，個人化醫療正成為一種趨勢，即生物製藥的開發旨在滿足個別患者的需求。法規結構正在不斷發展，以適應創新治療方法，從而創造有利於市場成長的環境，同時確保安全性和有效性。

主要趨勢和促進因素：

受生物技術和個人化醫療進步的推動，治療生物製藥市場正經歷強勁成長。單株抗體和基因療法的迅速發展是關鍵趨勢，它們正在革新慢性病和罕見疾病的治療選擇。癌症、自體免疫疾病和感染疾病的日益普遍推動了對生物製藥的需求，為患者提供標靶有效的治療方案。此外，監管部門對生物製藥的支持和加速核准流程正在加速其市場准入，並改善患者的用藥途徑。製藥公司不斷加大研發投入，促進創新，並拓展生物製藥產品線。同時，生物相似藥的日益普及也促進了市場成長，它們在保持療效的同時，提供了更具成本效益的替代方案。人工智慧（AI）和機器學習在生物製藥開發中的應用，正在推動藥物發現和開發流程的最佳化。新興市場蘊藏著許多機遇，這些市場的醫療基礎設施正在不斷改進，人們對生物製藥的認知也不斷提高。專注於策略聯盟和夥伴關係的公司能夠更好地掌握這些趨勢，實現持續的市場擴張。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 重組蛋白
    • 細胞療法
    • 基因治療
    • 疫苗
    • 融合蛋白
    • 抗體藥物複合體
    • 生物相似藥
  • 市場規模及預測：依產品分類
    • 治療性蛋白質
    • 胜肽類藥物
    • 酵素
    • 荷爾蒙
    • 血液凝固因子
    • 干擾素
    • 細胞激素
  • 市場規模及預測：依服務分類
    • 製造業
    • 研究與開發
    • 監管支持
    • 臨床試驗
    • 品質保證
    • 供應鏈管理
    • 生物製程
  • 市場規模及預測：依技術分類
    • 重組DNA技術
    • 融合瘤技術
    • 基因改造技術
    • CRISPR技術
    • 奈米科技
    • 生物列印
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 自體免疫疾病
    • 感染疾病
    • 心血管疾病
    • 神經系統疾病
    • 代謝性疾病
    • 罕見疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究所
    • 生物製藥公司
    • 受託研究機構
    • 學術機構
  • 市場規模及預測：依製程分類
    • 上游工程
    • 下游工藝
    • 配方
    • 填充和精加工
    • 包裝
  • 市場規模及預測：依發展狀況
    • 內部生產
    • 外包
    • 混合
  • 市場規模及預測：依設備分類
    • 生物反應器
    • 離心機
    • 層析法系統
    • 過濾系統

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Regeneron Pharmaceuticals
  • Vertex Pharmaceuticals
  • Sarepta Therapeutics
  • Bio Marin Pharmaceutical
  • Alnylam Pharmaceuticals
  • Moderna
  • Incyte
  • Alexion Pharmaceuticals
  • Biogen
  • Gilead Sciences
  • Amgen
  • Illumina
  • Jazz Pharmaceuticals
  • Novavax
  • Seagen
  • Genmab
  • Ipsen
  • UCB
  • Ascendis Pharma
  • CRISPR Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS32904

Biologics for Disease Treatment Market is anticipated to expand from $561.0 billion in 2024 to $1403.1 billion by 2034, growing at a CAGR of approximately 11.6%. The Biologics for Disease Treatment Market encompasses therapeutic products derived from living organisms, including monoclonal antibodies, vaccines, and cell therapies. These biologics target complex diseases such as cancer, autoimmune disorders, and infectious diseases. The market is driven by advancements in biotechnology, personalized medicine, and regulatory approvals, emphasizing efficacy and safety. Increasing prevalence of chronic diseases and demand for innovative treatments propel growth, with significant investment in research and development.

The Biologics for Disease Treatment Market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. The monoclonal antibodies segment stands out as the top-performing category, widely adopted for their specificity and efficacy in targeting diseases. Within this segment, oncology applications dominate, reflecting the urgent need for innovative cancer therapies. Following closely, the vaccines segment emerges as the second-highest performer, spurred by increasing emphasis on preventive healthcare and immunization programs. The rise in infectious diseases and the development of novel vaccine platforms contribute to this growth. The cell therapy sub-segment also shows promising potential, particularly in regenerative medicine and chronic disease management. The market is further bolstered by strategic partnerships and collaborations between biotech firms and pharmaceutical giants, fostering innovation and accelerating product development. Regulatory support and advancements in manufacturing technologies enhance market dynamics, ensuring a steady supply of high-quality biologics.

Market Segmentation
TypeMonoclonal Antibodies, Recombinant Proteins, Cell Therapy, Gene Therapy, Vaccines, Fusion Proteins, Antibody-Drug Conjugates, Biosimilars
ProductTherapeutic Proteins, Peptide Therapeutics, Enzymes, Hormones, Blood Factors, Interferons, Cytokines
ServicesManufacturing, Research and Development, Regulatory Support, Clinical Trials, Quality Assurance, Supply Chain Management, Bioprocessing
TechnologyRecombinant DNA Technology, Hybridoma Technology, Transgenic Technology, CRISPR Technology, Nanotechnology, Bioprinting
ApplicationOncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Metabolic Disorders, Rare Diseases
End UserHospitals, Clinics, Research Institutes, Biopharmaceutical Companies, Contract Research Organizations, Academic Institutions
ProcessUpstream Processing, Downstream Processing, Formulation, Fill and Finish, Packaging
DeploymentIn-house, Outsourced, Hybrid
DeviceBioreactors, Centrifuges, Chromatography Systems, Filtration Systems

In the Biologics for Disease Treatment Market, market share is dominated by a few key players, with pricing strategies reflecting the premium nature of biologics. The market is witnessing a surge in new product launches, driven by innovation and technological advancements. Companies are focusing on developing biologics that target specific diseases, enhancing their therapeutic efficacy. Pricing remains competitive, with manufacturers balancing cost-effectiveness and profitability. The market is characterized by strategic partnerships and collaborations, facilitating the introduction of novel biologics. Competition benchmarking reveals that established pharmaceutical giants maintain a strong foothold, yet emerging biotech firms are gaining traction through niche offerings. Regulatory influences are significant, with stringent guidelines impacting market dynamics. The FDA and EMA play pivotal roles in shaping the approval process, affecting the speed and success of product launches. Market data indicates a trend towards personalized medicine, with biologics tailored to individual patient profiles. The landscape is evolving, with regulatory frameworks adapting to accommodate innovative therapies, ensuring safety and efficacy while fostering market growth.

Geographical Overview:

The biologics for disease treatment market is witnessing substantial growth across various regions, each showcasing unique opportunities. North America remains a dominant force, driven by advanced healthcare infrastructure and significant investments in biologics research. The region's focus on innovative therapies and personalized medicine further bolsters its market position. Europe follows closely, benefiting from strong regulatory frameworks and a robust ecosystem for biologics development. The emphasis on sustainable healthcare solutions enhances Europe's market appeal. In the Asia Pacific, the market is expanding rapidly, propelled by rising healthcare expenditures and increasing prevalence of chronic diseases. Emerging economies like China and India are investing heavily in biologics manufacturing and research. Latin America and the Middle East & Africa are nascent markets with considerable potential. Brazil and Saudi Arabia are notable contributors, recognizing the importance of biologics in addressing unmet medical needs and driving healthcare advancements. These regions are poised for growth as they embrace innovative treatment solutions.

The biologics market for disease treatment is intricately influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea are bolstering their domestic biologics production capabilities to mitigate dependency on imports, while China accelerates innovation in biologics amid Western trade restrictions. Taiwan's pivotal role in biologics manufacturing is underscored by its geopolitical vulnerability, necessitating strategic alliances. The global biologics market is robust, driven by advances in personalized medicine and increasing prevalence of chronic diseases. By 2035, the market is anticipated to thrive on innovation and strategic regional partnerships. Concurrently, Middle East conflicts pose potential disruptions to energy supplies, affecting production costs and timelines globally, thereby underscoring the need for resilient and flexible supply chain strategies.

Key Trends and Drivers:

The biologics for disease treatment market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. Key trends include the surge in monoclonal antibodies and gene therapies, which are revolutionizing treatment options for chronic and rare diseases. The increasing prevalence of cancer, autoimmune disorders, and infectious diseases is propelling demand for biologics, offering targeted and effective therapeutic solutions. Moreover, regulatory support and expedited approval processes for biologics are enabling faster market entry, enhancing accessibility for patients. The growing investment in research and development by pharmaceutical companies is fostering innovation and expanding the biologics pipeline. Additionally, the rising adoption of biosimilars is contributing to market growth, providing cost-effective alternatives while maintaining therapeutic efficacy. The integration of artificial intelligence and machine learning in biologics development is optimizing drug discovery and development processes. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness of biologics is increasing. Companies focusing on strategic collaborations and partnerships are well-positioned to capitalize on these trends, ensuring sustained market expansion.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Device

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Recombinant Proteins
    • 4.1.3 Cell Therapy
    • 4.1.4 Gene Therapy
    • 4.1.5 Vaccines
    • 4.1.6 Fusion Proteins
    • 4.1.7 Antibody-Drug Conjugates
    • 4.1.8 Biosimilars
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Proteins
    • 4.2.2 Peptide Therapeutics
    • 4.2.3 Enzymes
    • 4.2.4 Hormones
    • 4.2.5 Blood Factors
    • 4.2.6 Interferons
    • 4.2.7 Cytokines
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Manufacturing
    • 4.3.2 Research and Development
    • 4.3.3 Regulatory Support
    • 4.3.4 Clinical Trials
    • 4.3.5 Quality Assurance
    • 4.3.6 Supply Chain Management
    • 4.3.7 Bioprocessing
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Recombinant DNA Technology
    • 4.4.2 Hybridoma Technology
    • 4.4.3 Transgenic Technology
    • 4.4.4 CRISPR Technology
    • 4.4.5 Nanotechnology
    • 4.4.6 Bioprinting
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Autoimmune Diseases
    • 4.5.3 Infectious Diseases
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Neurological Disorders
    • 4.5.6 Metabolic Disorders
    • 4.5.7 Rare Diseases
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Biopharmaceutical Companies
    • 4.6.5 Contract Research Organizations
    • 4.6.6 Academic Institutions
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
    • 4.7.3 Formulation
    • 4.7.4 Fill and Finish
    • 4.7.5 Packaging
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
    • 4.8.3 Hybrid
  • 4.9 Market Size & Forecast by Device (2020-2035)
    • 4.9.1 Bioreactors
    • 4.9.2 Centrifuges
    • 4.9.3 Chromatography Systems
    • 4.9.4 Filtration Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Device
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Device
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Device
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Device
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Device
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Device
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Device
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Device
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Device
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Device
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Device
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Device
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Device
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Device
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Device
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Device
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Device
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Device
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Device
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Device
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Device
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Device
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Device
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Device

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Regeneron Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Vertex Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Sarepta Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bio Marin Pharmaceutical
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Alnylam Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Moderna
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Incyte
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Alexion Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Biogen
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Gilead Sciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Amgen
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Illumina
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Jazz Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Novavax
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Seagen
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Genmab
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Ipsen
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 UCB
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Ascendis Pharma
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 CRISPR Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us